Moleculin Biotech (MBRX) announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia. This milestone triggers the final phase of preparation for the trial’s interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout
- Moleculin Biotech: Attractive Risk/Reward Ahead of Pivotal Annamycin Phase 3 Readout Supports Buy Rating and $10 Target
- Moleculin Biotech Updates Investors with New Corporate Presentation
- Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year
- Moleculin Biotech sees cash runway into 3Q26